QuidelOrtho Corp: insider trades · United States · SEC (Form 4)

About QuidelOrtho Corp

QuidelOrtho Corp. is a U.S.-based in vitro diagnostics company listed on Nasdaq under the ticker QDEL in the United States. The company is positioned as a global diagnostics specialist serving hospitals, clinical laboratories, transfusion medicine workflows, and point-of-care testing environments. Its business model centers on delivering fast, reliable, and increasingly automated diagnostic results across the care continuum. The portfolio spans clinical chemistry, immunoassay, immunohematology, molecular diagnostics, and rapid point-of-care testing, supported by reagents, consumables, software, and related services. ([quidelortho.com](https://www.quidelortho.com/us/en?utm_source=openai)) The current company was created through the merger of Quidel Corporation and Ortho Clinical Diagnostics, which closed on May 27, 2022. Quidel contributed a long legacy in rapid and decentralized testing, while Ortho brought scale in high-complexity laboratories and transfusion medicine. QuidelOrtho is headquartered in San Diego, California, at 9975 Summers Ridge Road. The company traces its innovation heritage back to 1979 through Quidel’s origins and highlights a combined history built on decades of diagnostic expertise. ([ir.quidelortho.com](https://ir.quidelortho.com/news/news-release-details/2022/QuidelOrtho-Formed-by-the-Completion-of-Transaction-Combining-Quidel-and-Ortho-Clinical-Diagnostics/default.aspx?utm_source=openai)) Operationally, QuidelOrtho’s core business lines include VITROS systems for clinical chemistry and immunoassay testing, SOFIA and QUICKVUE products for point-of-care use, ORTHO solutions for immunohematology and blood banking, and SOLANA and LYRA molecular platforms. The company also sells broad assay menus, laboratory software, and supporting consumables. QuidelOrtho states that it offers roughly 550 assays and serves more than 140 countries and territories, underscoring a sizable international footprint. ([quidelortho.com](https://www.quidelortho.com/us/en?utm_source=openai)) In competitive terms, QuidelOrtho is one of the larger pure-play in vitro diagnostics companies, with a diversified mix of centralized lab testing, transfusion medicine, and near-patient testing. Its competitive edge comes from breadth of menu, installed base, platform integration, and the ability to support customers across the full healthcare pathway, from hospitals and reference labs to clinics and retail-adjacent testing. Management has also emphasized that the business has been transitioning away from COVID-driven volatility toward a more durable and diversified diagnostics profile. ([ir.quidelortho.com](https://ir.quidelortho.com/news/news-release-details/2022/QuidelOrtho-Formed-by-the-Completion-of-Transaction-Combining-Quidel-and-Ortho-Clinical-Diagnostics/default.aspx?utm_source=openai)) Recent developments are important for investors. In February 2026, QuidelOrtho reported fourth-quarter and full-year 2025 results, citing growth in Labs and TRIAGE and further adjusted EBITDA margin expansion. In April 2026, it released preliminary first-quarter 2026 revenue and updated full-year guidance, reflecting a softer respiratory season and China-specific headwinds. The company also announced the acquisition of LEX Diagnostics in spring 2026, which adds an ultra-fast molecular platform for point-of-care testing and supports its strategic push into faster molecular diagnostics. For French-, Belgian- and Swiss-based investors, QDEL is therefore best viewed as a healthcare diagnostics name with exposure to hospital volumes, respiratory testing cycles, China demand, and execution on its industrial and M&A strategy. ([quidelortho.com](https://www.quidelortho.com/us/en/resources/press-releases/quidelortho-reports-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai))